GRAIL, Inc. (GRAL) vs RadNet, Inc. (RDNT)

GRAIL, Inc. and RadNet, Inc. are both Diagnostics & Research companies. RadNet, Inc. is the larger, with a market value of $6.1B against $5.3B — 1.2× the size. RadNet, Inc. grew revenue faster over the last twelve months: 18.9% against 17.5%. RadNet, Inc. has the higher net margin (−0.93% vs −243.8%) and the higher return on invested capital (2.24% vs −14.7%). Across the 17 metrics below, RadNet, Inc. leads on 13 and GRAIL, Inc. on 4.

Valuation

Metric GRAL RDNT Diagnostics & Research median
P/E n/m n/m 34.52
P/S 34.93 2.69 4.24
P/B 2.37 4.38 3.42
Price to free cash flow n/m 188.87 33.51
EV/EBITDA n/m 21.80 23.44
EV/Sales 29.76 2.96 5.18
Earnings yield (7.64%) (0.34%) (1.50%)
Free cash flow yield (5.36%) 0.53% 0.00%

Profitability

Metric GRAL RDNT Diagnostics & Research median
Gross margin 0.00% 11.53% 48.32%
Operating margin (347.28%) 3.12% (5.68%)
Net margin (243.80%) (0.93%) (4.10%)
Free cash flow margin (187.27%) 3.28% 0.00%
Return on equity (17.31%) (1.64%) 0.00%
Return on assets (15.24%) (0.55%) (6.05%)
Return on invested capital (14.74%) 2.24% 0.00%

Growth

Metric GRAL RDNT Diagnostics & Research median
Revenue growth (TTM) 17.47% 18.92% 8.99%
EPS growth (last fiscal year) 82.51% (725.00%) 20.36%
Revenue growth, 5-year CAGR — 13.74% 7.30%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric GRAL RDNT Diagnostics & Research median
Debt to equity 0.00 0.94 0.01
Current ratio 8.93 1.48 2.27
Net debt to EBITDA 2.27 1.16 0.68

Dividend

Metric GRAL RDNT Diagnostics & Research median
Dividend yield — — 0.67%
Payout ratio — — 0.20

Size

Metric GRAL RDNT Diagnostics & Research median
Market cap 5.32b 6.14b 2.22b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack